Takayuki Yoshino on the DESTINY-CRC01 trial

The Lancet Oncology in conversation with

English - June 01, 2021 22:00 - 5 minutes - 4.03 MB - ★★★★★ - 1 rating
Medicine Health & Fitness Education cancer radiotherapy chemotherapy mrna Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Roberto Orecchia on the ELIOT trial

Next Episode: Rafael Cardoso and Hermann Brenner on colorectal cancer

Takayuki Yoshino (National Cancer Center Hospital East, Kashiwa, Japan) discusses the DESTINY-CRC01 trial on trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00086-3/fulltext

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv